Biofrontera AG (ETR:B8FK)

Market Cap	14.40M
Revenue (ttm)	23.72M
Net Income (ttm)	-964.00K
Shares Out	6.08M
EPS (ttm)	-0.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,066
Average Volume	2,085
Open	2.400
Previous Close	2.420
Day's Range	2.370 - 2.400
52-Week Range	2.080 - 3.300
Beta	0.12
RSI	38.53
Earnings Date	May 31, 2025

About Biofrontera AG

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. It also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 88
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: B8FK

Financial Performance

In 2024, Biofrontera AG's revenue was 21.67 million, a decrease of -32.81% compared to the previous year's 32.25 million. Losses were -4.35 million, 1078.9% more than in 2023.